Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Pyxis Oncology (PYXS) over the last 5 years, with Dec 2024 value amounting to $9.7 million.

  • Pyxis Oncology's Gains from Investment Securities rose 32508.73% to $12.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.7 million, marking a year-over-year change of. This contributed to the annual value of $9.7 million for FY2024, which is 2082.26% up from last year.
  • As of FY2024, Pyxis Oncology's Gains from Investment Securities stood at $9.7 million, which was up 2,082.26% from $445,000 recorded in FY2023.
  • In the past 5 years, Pyxis Oncology's Gains from Investment Securities registered a high of $14.5 million during FY2022, and its lowest value of $445,000 during FY2023.
  • Over the past 3 years, Pyxis Oncology's median Gains from Investment Securities value was $9.7 million (recorded in 2024), while the average stood at $8.2 million.
  • As far as peak fluctuations go, Pyxis Oncology's Gains from Investment Securities spiked by 2,316.17% in 2022, and later tumbled by 96.93% in 2023.
  • Over the past 5 years, Pyxis Oncology's Gains from Investment Securities (Yearly) stood at $1.2 million in 2020, then tumbled by 49.41% to $600,000 in 2021, then spiked by 2,316.17% to $14.5 million in 2022, then crashed by 96.93% to $445,000 in 2023, then spiked by 2,082.26% to $9.7 million in 2024.